You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME

Advances in Rheumatoid Arthritis Treatments: From Pathophysiology to Treatment Options

  • Authors: Joel M. Kremer, MD
  • CME Released: 3/27/2015
  • THIS ACTIVITY HAS EXPIRED
  • Valid for credit through: 3/27/2016
Start Activity


Target Audience and Goal Statement

This activity is intended for rheumatologists, internal medicine physicians, and other clinicians who treat patients with rheumatoid arthritis (RA).

Among rheumatologists, internal medicine physicians, and other clinicians who treat patients with RA, responses to educational activity surveys and tests point to an inadequate understanding of the immune pathophysiology of disease, the role of cytokines in the RA inflammatory cascade, and the rationale for targeted therapies with novel mechanisms of action (MOAs). This gap in knowledge leads to a lack of competence/confidence among clinicians in advancing appropriate, MOA-driven interventions in a timely manner. To address the identified educational needs among clinicians who treat patients with RA in the UAB Health System and nationwide, this initiative provides expert perspective on the pathophysiology of RA, the MOAs of emerging therapies, and the role of these targeted therapies in optimizing outcomes for patients with RA. The initiative is designed as a curriculum that promotes learning through a comprehensive educational plan with a reinforcement component and offline resources.

Upon completion of this activity, participants will be able to:

  1. Recognize the mechanisms of action of emerging RA therapies within the immune cascade
  2. Identify anticipated benefits of therapy based on target components
  3. Assess the safety and efficacy of novel therapies for RA that target underlying pathophysiology to achieve treatment goals in patients with RA


Disclosures

As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.

Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.


Author

  • Joel M. Kremer, MD

    Pfaff Family Professor of Medicine, Albany Medical College; Director of Research, Center for Rheumatology, Albany, New York; CMO, Corrona International, LLC.

    Disclosures

    Disclosure: Joel M. Kremer, MD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for:
    Served as a speaker or a member of a speakers bureau for: Corrona International, LLC
    Received grants for clinical research from: AbbVie Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Lilly; Pfizer Inc
    Owns stock, stock options, or bonds from: Corrona International, LLC
    Other: Board member of: Corrona International, LLC

    Dr Kremer does intend to discuss off-label uses of drugs, mechanical devices, biologics, or diagnostics approved by the FDA for use in the United States.

    Dr Kremer does intend to discuss investigational drugs, mechanical devices, biologics, or diagnostics not approved by the FDA for use in the United States.

Editor

  • Emilie McCardell

    Scientific Director, Medscape, LLC

    Disclosures

    Disclosure: Emilie McCardell has disclosed no relevant financial relationships.

CME/Content Reviewer

  • Nafeez Zawahir, MD

    CME Clinical Director, Medscape, LLC

    Disclosures

    Disclosure: Nafeez Zawahir, MD, has disclosed no relevant financial relationships.

Course Director and Editor

  • Jeffrey R. Curtis, MD, MPH – Course Chair

    William J. Koopman Professor of Medicine at the University of Alabama at Birmingham School of Medicine, Director, Arthritis Clinical Intervention Program (ACIP), Associate Director, Center for Education and Research on Therapeutics of Musculoskeletal Disorders (CERTS)

    Disclosures

    Disclosure: Jeffrey R. Curtis, MD, MPH, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; CORRONA, Inc.; Crescendo Biologics; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc; Roche; UCB, Inc.
    Received grants for clinical research from: AbbVie Inc.; Amgen Inc.; Bristol-Myers Squibb Company; CORRONA, Inc.; Crescendo Biologics; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Pfizer Inc; Roche; UCB, Inc.


Accreditation Statements

    For Physicians

  • The University of Alabama School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    The University of Alabama School of Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME

Advances in Rheumatoid Arthritis Treatments: From Pathophysiology to Treatment Options

Authors: Joel M. Kremer, MDFaculty and Disclosures
THIS ACTIVITY HAS EXPIRED

CME Released: 3/27/2015

Valid for credit through: 3/27/2016

processing....

Abbreviations

ACPA = anti-citrullinated protein antibody
ACR = American College of Rheumatology
AE = adverse events
BID = twice a day
CDAI = Clinical Disease Activity Index
CMO = Chief Medical Officer
CRP = C-reactive protein
DARWIN 1 = Dose-finding Study of GLPG0634 as add-on to Methotrexate in Active Rheumatoid Arthritis Patients
DARWIN 2 = Dose-finding Study of GLPG0634 as Monotherapy in Active Rheumatoid Arthritis (RA) Patients
DAS28 = Disease Activity Score in 28 joints
DMARD = disease-modifying antirheumatic drug
ESR = erythrocyte sedimentation rate
EULAR = European League Against Rheumatism
FDA = US Food and Drug Administration
GM-CSF = granulocyte-macrophage colony-stimulating factor
gp = glycoprotein
H2O2 = hydrogen peroxide
HAQ-DI = Health Assessment Questionnaire for Rheumatoid Arthritis
HPA = hypothalamic-pituitary-adrenal (axis)
IL -1/6/17 = interleukin 1/6/17
IR = inadequate response
IV = intravenous
JAK = Janus kinase
MHC II = major histocompatibility complex class II
MMP = matrix metalloproteinase
MOA = mechanism of action
MTX = methotrexate
qw = every week
q2w = every 2 weeks
RA = rheumatoid arthritis
RANKL = receptor activator of nuclear factor kappa-B ligand
RRF = rheumatoid factor
SAE = serious adverse event
SAR = sarilumab
SC = subcutaneous
SDAI = Simple Disease Activity Index
STANDARD = Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis study
STAT = signal transducer and activator of transcription
TCZ = tocilizumab
TEAE = treatment-emergent adverse event
TGF = transforming growth factor
TNF = tumor necrosis factor
TNFI = tumor necrosis factor inhibitor
Tyk2 = tyrosine kinase 2
VEGF = vascular endothelial growth factor

« Return to: Advances in Rheumatoid Arthritis Treatments: From Pathophysiology to Treatment Options
  • Print